Description
Retatrutide – Triple GIP/GLP-1/Glucagon Receptor Agonist Research Peptide
Retatrutide, development code LY3437943, is a synthetic peptide of 39 residues carrying a fatty diacid side chain attached through the lysine at position 17. It was described in 2022 as a single molecule combining agonist activity at three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). The lipidation is a half-life extension strategy and is not itself a pharmacological element.
In the discovery report, the compound showed balanced activity at GCGR and GLP-1R with greater activity at GIPR in transfected cell systems, with half-maximal effective concentrations at the human receptors in the nanomolar and sub-nanomolar range. Work in genetically modified mouse lines was used to separate the contribution of each receptor: in obese mice, reductions in body weight were attributed partly to decreased calorie intake driven by GIPR and GLP-1R engagement and partly to increases in energy expenditure mediated through the glucagon receptor. A later structural study used cryo-electron microscopy to examine how one peptide accommodates three distinct receptor binding sites.
Retatrutide is an investigational compound. All descriptions here refer to published cell and animal work.
Key Research Areas
Multi-Receptor Pharmacology: Used in receptor-transfected cell lines to characterize binding affinity and cyclic AMP responses at GIPR, GLP-1R and GCGR, and to compare triple agonism against single and dual agonists.
Energy Expenditure: Studied in rodent models using indirect calorimetry, where the glucagon receptor component is examined as the element distinguishing this molecule from incretin-only agonists.
Receptor Deconvolution in Knockout Models: Investigated in genetically modified mouse lines lacking individual receptors, to assign each functional effect to a defined target.
Glucose Handling: Examined in intraperitoneal glucose tolerance testing in mice, and in models of diet-induced obesity, as a readout of combined incretin receptor engagement.
Structural Biology: Applied in cryo-electron microscopy work on the structural basis of unimolecular polypharmacology at class B G protein-coupled receptors.
Peptide Lipidation Chemistry: Studied as an example of fatty diacid acylation used to extend circulating half-life in peptide design.
Product Details
- Name: Retatrutide
- Type: Research peptide
- Available strengths: 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg
- Form: Lyophilized powder
- Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
- Molecular Weight: 4731.42 g/mol
- Purity: ≥98% (HPLC verified)
- Storage: Store at 2–8°C, protected from light and moisture
- Use: For laboratory research use only. Not for human consumption.
- What’s Included: 1 × Retatrutide vial (lyophilized peptide), 1 × 3 mL bacteriostatic water vial, 1 × mixing syringe, 4 × insulin syringes, 4 × alcohol wipes
Selected literature
- Coskun T., Urva S., Roell W.C., et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022;34(9):1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013


